Kristina Jankovic, Medical Oncology Resident at the University Clinical Center Niš, shared a recent article by Asher Mullard on X:
“Oncology leads the way.
In 2024, the FDA approved 50 new therapies, with 15 (30%) targeting cancer – including multiple first-in-class therapies and the 11th PD1/PDL1 inhibitor.”
Author: Asher Mullard
Kristina Jankovic, MD, is a Medical Oncology Resident at the University Clinical Center Niš, where she works at the Oncology Clinic. Her primary interests include breast cancer, innovative cancer therapies, oncofertility, and hereditary cancers. She is a member of ESMO, ASCO, and the European School of Oncology (ESO).
For more updates, follow OncoDaily.
